Naloxone 911: Strategies for Community Pharmacists

Activity Preview

With drug overdose as the leading cause of death due to unintentional injury in the United States—and opioids the most common cause of fatal overdoses—the time for epidemic-ending intervention is now. Through proper medication management, overdose risk-reduction education, and provision of naloxone rescue kits to the community, pharmacists can play a vital role. Learn about the existing laws pertaining to naloxone, the available products, and the logistics of dispensing them. 

Learning Objectives

At the completion of this activity, pharmacists will be able to: 

  1. Explore strategies and legislation aimed at reducing the growth of opioid-related overdose
  2. Identify patients at-risk of opioid overdose.
  3. Distinguish the different naloxone formulations, mechanism of action, and safety and efficacy profile.
  4. Illustrate pharmacist communication strategies in educating patients about naloxone and dispensing naloxone without a prescription.

Activity type: Application-based
Target Audience: Pharmacists
Learning Level: 2

Accreditation Information

ACPE Logo

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The following archived webinar is approved for 1.5 contact hour of CPE credit (0.15 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-20-053-H08-P.

To obtain credit for completing Naloxone 911: Strategies for Community Pharmacists. participants will need to watch the archived webinar, complete the assessment with a grade of 70% or better, complete the evaluation questions, and then CLAIM credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.    

APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education assessment. Please note that you will not be permitted to submit the assessment a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.

Initial release date: April 1, 2020
Expiration date: March 21, 2023 - No credit granted after this date

Development

Naloxone 911: Strategies for Community Pharmacists is an activity for pharmacists developed by the American Pharmacists Association. © 2020 American Pharmacists Association

Disclosures

Anita Jacobson, PharmD is the principal investigator on a Rural Opioid Technical Assistance grant from SAMHSA: TI082562-01Thomas Franko, PharmD and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures

Conflicts of interest have been resolved through content review by Helen Sairany, BA, PharmD, MBA, BCACP, Director of Content Development & Partnership at the American Pharmacists Association. 

Fee

This learning product is a component of the APhA2020 Virtual Education package.

System Requirements

Computer and internet access are required to complete this activity.  Please visit our website to view the Technology System Requirements in order to have a positive learning experience.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE# 0202-0000-20-053-H08-P 0.15 CEUs March 21, 2020 - March 21, 2023